The document describes a mobile device called the RheoCardioMonitor that non-invasively monitors cardiac function through ECG and ICG signals. It analyzes the data in real-time. The author is seeking partners for clinical trials of a prototype to obtain certification. Sales are projected to be 15 devices in 2014, growing to 320 devices in 2017 as the technology adds channels, functionality and algorithms. Competitors provide less mobility, require a physician for measurement, or cost more. The author and advisors have expertise in relevant areas and are seeking partners for production, support, and sales to commercialize the technology.